SurModics (NASDAQ: SRDX) reported Q3 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $17.8 million versus the consensus estimate of $15.98 million.

• FDA approves 446 patient SurVeil® DCB Pivotal Study
• Total Revenue of $17.8 Million
• EPS of $0.05, Non-GAAP EPS of $0.09
• Increases financial outlook for fiscal 2017

GUIDANCE:

SurModics sees FY2017 EPS of $0.29-$0.39, versus the consensus of $0.19. SurModics sees FY2017 revenue of $70-72 million, versus the consensus of $67.59 million.

For earnings history and earnings-related data on SurModics (SRDX) click here.